Kaylee Williams, PA
Surgical · Dallas, TXNPI 1073751723
Payments from drug & device makers
Across 110 payments — averaging $19.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exeltis, USA Inc.$288
- Organon$263
- Therapeuticsmd, Inc.$209
- Mayne Pharma Commercial LLC$209
- Merck$144
- AbbVie$109
- plus $927 from 22 others
What the payments were for
- Food & beverage$2,149100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Exeltis, USA Inc. | 16 | $288 |
| Organon | 13 | $263 |
| Therapeuticsmd, Inc. | 12 | $209 |
| Mayne Pharma Commercial LLC | 9 | $209 |
| Merck | 7 | $144 |
| AbbVie | 6 | $109 |
| Daiichi Sankyo Inc. | 5 | $88 |
| Exact Sciences | 4 | $85 |
| Sage Therapeutics, LLC | 4 | $84 |
| Evofem Biosciences, Inc. | 3 | $72 |
| Millicent US Inc | 3 | $66 |
| Pfizer | 3 | $63 |
| Coopersurgical, Inc. | 2 | $55 |
| Avion Pharmaceuticals | 3 | $54 |
| Astellas Pharma US Inc | 3 | $51 |
| Myovant Sciences Inc. | 3 | $46 |
| Supernus Pharmaceuticals, Inc. | 2 | $40 |
| Lupin Inc. | 2 | $33 |
| EBI, LLC | 1 | $27 |
| Acacia Pharma Inc | 1 | $23 |
| Bayer | 1 | $22 |
| Mission Pharmacal Company | 1 | $20 |
| Minerva Surgical, Inc | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Mylan Pharmaceuticals Inc. | 1 | $16 |
| Pacira Pharmaceuticals Incorporated | 1 | $15 |
| AMAG Pharmaceuticals, Inc. | 1 | $15 |
| Channel Medsystems, Inc. | 1 | $13 |
How this compares
$2,149 in reported general payments places this provider in the 80th percentile of 804 surgical providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 34 | $2,611 |
| Clobetasol Propionate | 23 | $2,247 |
| ValacyclovirValacyclovir Hcl | 12 | $508 |
| Fluconazole | 14 | $115 |
Paid to pharmacies, not to this prescriber.
Other surgical in Dallas
- Josephine KarlDallas$18K
- Lonnie GinnDallas$17K
- Gretchen WilsonDallas$16K
- Jessica GreenemeierDallas$9K
- Kriste HaileDallas$8K
- Erin TenneyDallas$8K
- Brittany BuckmasterDallas$7K
- Bryn BumpasDallas$6K
- Kelly CampbellDallas$5K
- Dallin WoottonDallas$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.